ʻO nā Cellular Therapies ka wā e hiki mai ana o ka maʻi Autoimmune?

Hiki paha i kahi lāʻau lapaʻau kipi no nā maʻi kanesa ke mālama a hoʻonohonoho hou i ka ʻōnaehana pale e hāʻawi i ke kala ʻana no ka manawa lōʻihi a i ʻole e ho'ōla paha i kekahi mau maʻi. Nā maʻi Autoimmune.

Ua hāʻawi ka Chimeric antigen receptor (CAR) T-cell therapy i kahi ala hou no ka mālama ʻana i nā maʻi ʻaʻai hematologic mai ka makahiki 2017, akā aia nā hōʻailona mua e hiki ke hoʻohana hou ʻia kēia mau immunotherapies cellular no nā maʻi autoimmune i hoʻopili ʻia e B-cell.

I Kepakemapa o ka makahiki i hala, ua hōʻike nā kānaka noiʻi ma Kelemania he ʻelima mau maʻi me ka refractory systemic lupus erythematosus (SLE) i mālama ʻia me ka lāʻau lapaʻau CAR T-cell i loaʻa i ka hoʻokuʻu ʻole ʻia o ka lāʻau. I ka manawa o ka paʻi ʻana, ʻaʻohe maʻi i hoʻi hou a hiki i 17 mau mahina ma hope o ka mālama ʻana. Ua wehewehe nā mea kākau i ka seroconversion o nā antibodies antinuclear i ʻelua mau maʻi me ka hahai lōʻihi loa, "e hōʻike ana e hiki i ka hoʻopau ʻana i nā clones B-cell autoimmune ke alakaʻi i kahi hoʻoponopono ākea o ka autoimmunity," kākau nā kānaka noiʻi.

Ma kekahi hihia ʻē aʻe i paʻi ʻia i Iune, ua hoʻohana nā kānaka noiʻi i nā pūnaewele CAR-T i hoʻopili ʻia me CD-19 e mālama i kahi kāne he 41 makahiki me ka maʻi antisynthetase refractory me ka myositis holomua a me ka maʻi māmā interstitial. ʻEono mahina ma hope o ka mālama ʻana, ʻaʻohe hōʻailona o ka myositis ma ka MRI a ua hōʻike kahi scan CT umauma i ka regression piha o ka alveolitis.

Mai ia manawa, ua hāʻawi mua ʻia nā ʻoihana biotechnology ʻelua - ʻo Cabaletta Bio ma Philadelphia a me Kyverna Therapeutics ma Emeryville, Kaleponi - i nā hoʻolālā wikiwiki mai ka US Food and Drug Administration no ka CAR T-cell therapy no SLE a me lupus nephritis. Ke hana nei ʻo Bristol-Myers Squibb i kahi hoʻokolohua pae 1 i nā poʻe maʻi me ka SLE koʻikoʻi a paʻakikī hoʻi. Ke hana nei kekahi mau ʻoihana biotechnology a me nā haukapila ma Kina i nā hoʻokolohua lapaʻau no SLE. Akā ʻo kēia wale nō ka piko o ka iceberg e pili ana i nā therapies cellular no ka maʻi autoimmune, wahi a Max Konig, MD, PhD, he polopeka kōkua o ka lāʻau lapaʻau ma ka mahele o ka rheumatology ma ke Kula Lapaʻau ʻo Johns Hopkins University ma Baltimore.

"He manawa hoihoi loa kēia. He mea i ʻike mua ʻole ʻia ma ka mōʻaukala o ka autoimmunity," wahi āna.

He "Reboot" no ka ʻōnaehana pale

Ua puni nā lāʻau lapaʻau i hoʻopaʻa ʻia me nā cell B mai ka hoʻomaka ʻana o nā makahiki 2000 me nā lāʻau lapaʻau e like me rituximab, kahi lāʻau lapaʻau antibody monoclonal e hoʻopaʻa ana iā CD20, kahi antigen i hōʻike ʻia ma ka ʻili o nā cell B. Hoʻopaʻa nā cell CAR T i loaʻa i kēia manawa i kahi antigen ʻili ʻē aʻe, CD19, a he lāʻau lapaʻau ikaika loa. Loaʻa nā mea ʻelua i ka hoʻopau ʻana i nā cell B i ke koko, akā hiki i kēia mau cell T i hoʻopaʻa ʻia me nā CD19 i hana ʻia ke hiki i nā cell B e noho ana i loko o nā ʻiʻo ma ke ʻano ʻaʻole hiki i nā lāʻau lapaʻau antibody, wahi a Konig.